| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/06/2000 | WO2000024899A3 Interleukin-1 homolog zil1a4 |
| 07/06/2000 | WO2000021988A3 Human ankyrin family protein |
| 07/06/2000 | WO2000020619A3 Secreted renilla luciferase |
| 07/06/2000 | WO2000020612A3 Therapeutically active proteins in plants |
| 07/06/2000 | WO2000020607A3 Chimaeric proteins between members of tgf-beta superfamily |
| 07/06/2000 | WO2000020591A3 Tgf-beta superfamily mutant members, including morphogenic proteins |
| 07/06/2000 | WO2000020588A3 Bone marrow-derived serum proteins |
| 07/06/2000 | WO2000020584A3 Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 |
| 07/06/2000 | WO2000020025A3 Akt compositions for enhancing survival of cells |
| 07/06/2000 | WO2000020024A3 Methods for the treatment of non-thyroid disorders |
| 07/06/2000 | WO2000020023A3 Null igf for the treatment of cancer |
| 07/06/2000 | WO2000020020A3 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 07/06/2000 | WO2000018954A3 Use of pex in the treatment of metabolic bone diseases |
| 07/06/2000 | WO2000018903A3 Inducible genetic suppression of cellular excitability |
| 07/06/2000 | WO2000018419A3 Methods for administration of antibiotics |
| 07/06/2000 | WO2000018417A3 Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine |
| 07/06/2000 | WO2000017355A3 Human cytoskeleton associated proteins |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000015770A3 Human serine/threonine protein kinases |
| 07/06/2000 | WO2000014222A3 Gabab receptor subtypes gabab-r1c and gabab-r2 and heterodimers thereof |
| 07/06/2000 | WO2000014219A3 Peptide nucleic acid-oligoadenylate chimeric molecules |
| 07/06/2000 | WO2000013703A3 Methods of treating hypertension and compositions for use therein |
| 07/06/2000 | WO2000011028A3 Anti-inflammatory peptides derived from il-2 and analogues thereof |
| 07/06/2000 | WO2000010613A3 Inhibition of smooth muscle cell migration by heme oxygenase 1 |
| 07/06/2000 | WO2000000616A3 Marburg virus vaccines |
| 07/06/2000 | WO1999065516A9 Methods and compositions for treating diseases mediated by transglutaminase activity |
| 07/06/2000 | WO1999064035A9 β2-ADRENERGIC RECEPTOR AGONISTS |
| 07/06/2000 | WO1999063087A9 G-protein coupled receptor, named 2871 receptor |
| 07/06/2000 | WO1999061600A9 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/06/2000 | WO1999054461A3 Human nucleic acid sequences of endometrium tumour tissue |
| 07/06/2000 | WO1999054448A3 Human nucleic acid sequences, increased expression thereof in uterus myoma tissue |
| 07/06/2000 | WO1999054447A3 Human nucleic acid sequences of bladder tumour tissue |
| 07/06/2000 | WO1999053040A3 Human nucleic acid sequences from ovarian tumour tissue |
| 07/06/2000 | WO1999052514A3 Pharmaceutical composition and combination preparation for immunosuppressive therapy |
| 07/06/2000 | WO1999051727A3 Human nucleic acid sequences of normal ovary tissue |
| 07/06/2000 | WO1999047655A3 Human nucleic acid fragments with heightened expression in normal breast tissue |
| 07/06/2000 | WO1999046375A3 Human nucleic acid sequences from prostate tissue |
| 07/06/2000 | WO1999046374A3 Human nucleic acid sequences from prostate tumour tissue |
| 07/06/2000 | WO1999041282A8 Therapeutic uses of keratinocyte growth factor-2 |
| 07/06/2000 | WO1999040119A9 Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it |
| 07/06/2000 | WO1999026649A9 Methods and compositions for inhibiting hiv infectivity and blocking chemokine activity |
| 07/06/2000 | DE19860642A1 Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen An antisense oligonucleotide for inhibiting the expression of the adhesion molecule very late antigen-4 (VLA-4) in human cells |
| 07/06/2000 | DE19859486A1 New peptide with high antiproliferative activity, useful for treating cancer or psoriasis, comprises a nuclear localization sequence and a fragment of the retinoblastoma protein |
| 07/06/2000 | DE19858188A1 Apparatus for dissolving albumin flakes in a liquid contained in a bottle of circular cross-section. |
| 07/06/2000 | CA2363999A1 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 07/06/2000 | CA2358385A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 07/06/2000 | CA2356955A1 Stable subtilin and methods of manufacture |
| 07/06/2000 | CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356894A1 Removal of biological contaminants |
| 07/06/2000 | CA2356877A1 Gene therapy for pulmonary edema using adenovirus vectors encoding na,k-atpase |
| 07/06/2000 | CA2356834A1 Methods for reducing adverse side effects associated with cellular transplantation |
| 07/06/2000 | CA2356777A1 Pseudopeptide compounds having an inhibiting activity with respect to paths activated by proteins with active tyrosine kinase activity and pharmaceutical compositions containing same |
| 07/06/2000 | CA2356755A1 Superantigens |
| 07/06/2000 | CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356661A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines |
| 07/06/2000 | CA2356608A1 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides abd uses thereof |
| 07/06/2000 | CA2356606A1 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356551A1 Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| 07/06/2000 | CA2356548A1 Human brainiac-5 |
| 07/06/2000 | CA2356542A1 Peptidoglycan recognition proteins |
| 07/06/2000 | CA2356462A1 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356459A1 Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356424A1 Serine protease inhibitor |
| 07/06/2000 | CA2356402A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | CA2356382A1 Agent for treating visual cell function disorder |
| 07/06/2000 | CA2356302A1 Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356186A1 Penicillins as pharmaceuticals for the downregulation of ifn.gamma. production |
| 07/06/2000 | CA2356057A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | CA2355744A1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2000 | CA2355632A1 Ucp-2 promoter dna |
| 07/06/2000 | CA2355468A1 Glycosyl phosphatidy linositol specific phospholipase d proteins and uses thereof |
| 07/06/2000 | CA2355281A1 Thrombin inhibitors |
| 07/06/2000 | CA2355271A1 Cyclosporin solution |
| 07/06/2000 | CA2355254A1 Use of peptide |
| 07/06/2000 | CA2354431A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | CA2334958A1 Peptide mimics useful for treating disease |
| 07/06/2000 | CA2321672A1 Caspase-8 interacting proteins |
| 07/06/2000 | CA2318356A1 Pharmaceutical formulation containing a hyaluronic acid-splitting enzyme of microbial origin |
| 07/05/2000 | EP1016727A1 Gene therapy to promote angiogenesis. |
| 07/05/2000 | EP1016726A1 Gene therapy to promote angiogenesis |
| 07/05/2000 | EP1016721A1 NOVEL Fas LIGAND DERIVATIVE |
| 07/05/2000 | EP1016720A1 Mammalian genes participating in circadian period |
| 07/05/2000 | EP1016716A2 Dna encoding a growth factor specific for epithelial cells |
| 07/05/2000 | EP1016715A1 Oligonucleotides having a conserved G4 core sequence |
| 07/05/2000 | EP1016714A1 Novel plasmid dna containing reporter gene dna and use of the same |
| 07/05/2000 | EP1016673A1 Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer |
| 07/05/2000 | EP1016672A1 Polypeptide transition metal salts and method of enhancing anti-hiv activity of polypeptide |
| 07/05/2000 | EP1016671A2 Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) |
| 07/05/2000 | EP1016670A1 Glycopeptide antibiotic derivatives |
| 07/05/2000 | EP1016418A2 Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| 07/05/2000 | EP1016415A2 Use of a fibrin glue for the regeneration of tissue |
| 07/05/2000 | EP1016414A2 Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans |
| 07/05/2000 | EP1016413A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 07/05/2000 | EP1016412A1 Dental remedies containing pth |
| 07/05/2000 | EP1016405A2 Arylating medicaments |
| 07/05/2000 | EP1015889A1 dsRNA/dsRNA-BINDING PROTEIN METHODS AND COMPOSITIONS |
| 07/05/2000 | EP1015630A1 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 07/05/2000 | EP1015625A2 Reagents and methods useful for detecting diseases of the prostate, breast and ovary |
| 07/05/2000 | EP1015616A2 Intrabody-mediated control of immune reactions |
| 07/05/2000 | EP1015615A1 Targeted gene transfer using g protein coupled receptors |